For each component of major adverse cardiovascular event, SGLT2i had no effect on stroke while GLP-1 receptor agonists significantly reduced stroke (HR, 0.86; 95% CI, 0.77–0.97; p = 0.012). This evidence concerns the gene GLP1R and stroke disorder.